Increased serum S100A12 levels are associated with higher risk of acute heart failure in patients with type 2 diabetes.
Barnabas GellenNathalie Thorin-TrescasesEric ThorinElise GandStephanie RagotDavid MontaigneYann PucheuKamel MohammediPhilippe GataultLouis PotierEvelyne LiuuSamy HadjadjPierre-Jean Saulniernull nullPublished in: ESC heart failure (2022)
In patients with type 2 diabetes, increased serum S100A12 concentration is independently associated with risk of HHF, but not with risk of MACE. Compared with NT-proBNP, the potential clinical interest of S100A12 for the prediction of HF events remains limited. However, S100A12 could be a candidate for a multimarker approach for HF risk assessment in diabetic patients.